Mike Stadnisky is the Managing Director of Thielsen Capital, a seed-stage financing syndicate network uniting life science investors, operators, and innovators to drive exceptional outcomes for founding teams and science—built on the simple thesis that operators investing in operators produce better companies.
Before founding Thielsen, Mike spent decades at the front lines of life science tools, building and exiting companies that redefined how scientists measure and analyze biology. As CEO of FlowJo, he led the world's leading flow cytometry analysis platform before its acquisition by BD, then stayed on as VP & GM of Informatics at BD Life Sciences to scale what he had built. He followed that by co-founding Phitonex, a DNA nanotechnology startup pioneering next-generation fluorescent reagents for single-cell analysis, which Thermo Fisher acquired in 2020—his second successful exit. Along the way, he authored 10 patents, won the 2019 International Society for the Advancement of Cytometry Innovation Award, and brought his operator playbook into the classroom as a lecturer at MIT Sloan.
At Thielsen Capital, Mike backs the picks-and-shovels companies that make the entire life science ecosystem run—seed-stage tools businesses where his hard-won experience across the bench, the boardroom, and two acquisitions gives founders a partner who has navigated every stage of the journey firsthand.
